Rezdiffra (Resmetirom) in Children Under 12: What Families and Clinicians Need to Know About Transition to Adult Care

Why Resmetirom Is Not Currently Available to Children Under 12

Resmetirom is a thyroid hormone receptor beta (THR-beta) selective agonist approved by the FDA on March 14, 2024, under the brand name Rezdiffra. The approval was granted specifically for adults with noncirrhotic nonalcoholic steatohepatitis (MASH) accompanied by moderate-to-advanced liver fibrosis (stage F2 or F3). The prescribing label contains no pediatric dosing section for patients under 18, and there are no completed clinical trials evaluating resmetirom in children of any age.

The Regulatory Basis for the Age Restriction

The FDA's approval of Rezdiffra rested on data from the MAESTRO-NASH trial, a Phase 3, randomized, double-blind study enrolling 966 adult participants. At 52 weeks, resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of participants vs. 14.2% placebo (P<0.001), and fibrosis improvement by at least one stage in 24.2% vs. 14.2% placebo (P<0.001) [1]. Every enrolled participant was an adult. No sub-group data exist for adolescents or children.

Per the FDA Pediatric Research Equity Act (PREA), sponsors of drugs approved for adult conditions that could plausibly affect pediatric populations are required to submit pediatric study plans. As of the date of this publication, no completed pediatric assessment for resmetirom has been posted to the FDA website or registered as a completed study on ClinicalTrials.gov [2].

Thyroid Hormone Receptor Biology in the Developing Child

THR-beta receptors are expressed in the liver, pituitary gland, and cochlea. In adults, resmetirom's hepatic selectivity limits off-target thyroid-axis suppression at approved doses. In children, however, thyroid hormones direct bone maturation, central nervous system myelination, and pubertal development. The American Thyroid Association guidelines note that pediatric thyroid hormone homeostasis differs substantially from adult physiology through at least early adolescence [3]. Exposing a child under 12 to a THR-beta agonist carries theoretical risks that have not been assessed in any published preclinical pediatric model specific to resmetirom.

This is not a bureaucratic barrier. It is a genuine knowledge gap that requires purpose-designed pediatric pharmacokinetic and safety studies before any clinical use in this age group.

How MASLD and MASH Present in Children Under 12

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called NAFLD, is the most common chronic liver condition in children across high-income countries [4]. Prevalence in the general pediatric population is approximately 10%, rising to 34-38% among children with obesity [5].

Histological Differences From Adult Disease

Pediatric MASLD has a distinct histological pattern. A landmark analysis by Schwimmer et al. Published in Hepatology described a "type 2" pattern in children: portal-predominant inflammation and fibrosis rather than the pericentral pattern typical of adults [6]. This difference has direct implications for trial design and drug targeting. Resmetirom's mechanism targets hepatic lipid metabolism and inflammatory signaling pathways that may behave differently in this portal-predominant pediatric pattern.

Fibrosis Progression in Childhood

Fibrosis can progress in children, including those under 12. A prospective cohort study following 100 children with biopsy-confirmed NAFLD found that 17% showed fibrosis progression over an average follow-up of 41 months, with younger age and higher ALT being independent predictors [7]. Children who enter adolescence with stage F2 or greater fibrosis are precisely the population who will need to be evaluated for pharmacotherapy, including resmetirom, once they reach adulthood and meet approved criteria.

Current Standard of Care for Children Under 12

No pharmacologic agent has received FDA approval specifically for pediatric MASLD or MASH. The current standard of care rests on three pillars:

• Lifestyle modification targeting at least 7-10% body weight reduction in children with obesity, consistent with NASPGHAN clinical practice guidelines [8]
• Management of metabolic comorbidities: insulin resistance, dyslipidemia, hypertension
• Monitoring with serial hepatic ultrasound and liver enzymes at 6-12 month intervals, with biopsy reserved for diagnostic uncertainty or clinical trial enrollment

Vitamin E at 800 IU/day showed histological improvement in the TONIC trial (N=173 pediatric participants), though without statistically significant benefit on the primary endpoint of ALT reduction [9]. Metformin showed no histological benefit in the same trial. These data underline how few options exist for children awaiting the eventual transition to adult pharmacotherapy.

Planning the Transition to Adult Hepatology: A Clinical Framework

Transition from pediatric to adult care is a process, not a single handoff appointment. For a child diagnosed with MASLD under age 12, the transition timeline spans years. Starting structured preparation by age 14-16 is the standard endorsed by the American Academy of Pediatrics (AAP), which recommends that all youth with chronic conditions receive a written transition plan by age 14 [10].

Phase 1: Building the Medical Record Before Transfer (Ages 12-16)

The pediatric hepatologist should compile a comprehensive transition document that includes:

• Full biopsy history with NAS (NAFLD Activity Score) and fibrosis stage at each time point
• Longitudinal metabolic data: HbA1c, fasting lipids, ALT, AST, GGT, platelet count
• BMI trajectory and any weight-management interventions attempted
• Family history of cirrhosis, hepatocellular carcinoma, or metabolic syndrome
• A summary of all prior pharmacologic trials and their outcomes

This record becomes the foundation for the adult hepatologist's initial assessment. Resmetirom candidacy in adulthood will depend partly on fibrosis stage confirmed by biopsy or validated non-invasive tests such as FibroScan (liver stiffness measurement). An adolescent who reaches age 18 with undocumented disease trajectory may face significant diagnostic delays in the adult system.

Phase 2: Transition Readiness Assessment (Ages 16-18)

Transition readiness describes a young patient's capacity to manage their own condition. The Transition Readiness Assessment Questionnaire (TRAQ) is a validated 20-item tool measuring self-management skills across five domains. NASPGHAN's 2023 position statement on transition in pediatric liver disease recommends formal readiness assessment using validated instruments [11].

Readiness gaps commonly identified in adolescents with MASLD include:

• Poor understanding of their fibrosis stage and what it means for long-term prognosis
• No established relationship with a primary care provider who manages metabolic comorbidities
• Gaps in understanding dietary triggers and the connection between insulin resistance and liver injury

Addressing these gaps before transfer reduces the risk of the well-documented "cliff effect," where young adults disengage from care in the first 12-24 months after transfer to adult services.

Phase 3: The Transfer Appointment and Adult Provider Selection (Age 18-21)

The transfer appointment should occur with both the pediatric and adult providers present, or at minimum with a structured warm handoff letter sent in advance. The adult hepatologist receiving the patient should have experience managing metabolic liver disease and familiarity with approved MASH pharmacotherapies.

At this appointment, the adult provider will reassess:

• Current fibrosis stage using FibroScan, ELF score, or liver biopsy
• Whether the patient meets current prescribing criteria for approved agents
• Eligibility for ongoing or upcoming clinical trials

Patients with F2 or F3 fibrosis who have not progressed to cirrhosis, who have a BMI consistent with metabolic risk, and who have documented MASH on biopsy may qualify for resmetirom at approved doses (80 mg or 100 mg daily based on body weight) under the current label [2].

Resmetirom's Mechanism: Why It Matters for Long-Term Planning

Understanding how resmetirom works helps families and pediatric providers explain why it cannot simply be used earlier and why it becomes relevant once approved criteria are met in adulthood.

THR-Beta Selectivity and Hepatic Lipid Reduction

Resmetirom selectively activates thyroid hormone receptor beta in hepatocytes. This drives expression of genes involved in mitochondrial fatty acid beta-oxidation and reduces de novo lipogenesis. In MAESTRO-NASH, resmetirom 100 mg reduced LDL cholesterol by 16.3% and triglycerides by 22.6% vs. Placebo at 52 weeks [1]. These lipid effects are independent of dietary changes and represent a mechanism distinct from GLP-1 receptor agonists or PPAR agonists.

Why Beta-Oxidation Upregulation Carries Developmental Risk

In children, mitochondrial fatty acid oxidation capacity is proportionally higher than in adults due to higher metabolic rate per kilogram of body weight. The net effect of pharmacologically amplifying this pathway in a growing child is unknown. Pediatric pharmacologists at the FDA require age-stratified PK/PD modeling before any pediatric trial can begin, per 21 CFR 314.55 regulations governing pediatric studies [12].

Lipid-Lowering Effects and Growth

Cholesterol is a structural component of cell membranes and a precursor for steroid hormones including sex hormones driving puberty. A 16% reduction in LDL in an adult with established cardiovascular risk is a favorable outcome. The same reduction in a pre-pubertal child theoretically intersects with hormonal development in ways that require study. This biological rationale explains why the FDA has not granted any THR-beta agonist pediatric approval to date.

Non-Pharmacologic Interventions Bridging Childhood to Adult Eligibility

Because no approved pharmacotherapy exists for children under 12 with MASLD, the years between diagnosis and potential adult eligibility for resmetirom must be spent aggressively managing modifiable risk factors.

Weight Management Programs

Structured, multidisciplinary weight management programs produce meaningful hepatic benefits in children. A meta-analysis of 11 randomized controlled trials in pediatric NAFLD found that lifestyle interventions reduced ALT by a weighted mean of 14.6 IU/L compared to control (P<0.001), with improvements in hepatic steatosis on imaging [13]. Programs combining dietary counseling, physical activity, and behavioral therapy outperform single-component approaches.

The NASPGHAN guideline recommends targeting a 10% reduction in BMI z-score as a threshold associated with histological improvement. Sustaining this reduction through adolescence may prevent fibrosis progression and reduce the disease severity the patient carries into adulthood.

GLP-1 Receptor Agonists in Adolescents

While resmetirom is not available to pediatric patients, some adolescents aged 12 and older with obesity may be eligible for semaglutide (Wegovy), which received FDA approval for chronic weight management in adolescents 12 and older in December 2022 [14]. Semaglutide does not carry a specific MASH indication, but weight reduction of 10% or greater is associated with histological regression of MASH in adult studies. Its use in the 12-17 age range, when metabolically appropriate and supervised, may slow liver disease progression ahead of eventual adult transition.

Ursodeoxycholic Acid and Antioxidants

UDCA has not shown consistent histological benefit in pediatric NAFLD and is not recommended as a primary treatment by current guidelines. Vitamin E at 800 IU/day remains the option with the most pediatric trial data, though the TONIC trial's primary endpoint was not met. Families should be counseled that these agents manage risk rather than reverse established fibrosis.

What Families Should Ask Before and During Transition

Families navigating a child's diagnosis under age 12 often encounter confusion about future treatment options. These are the concrete questions that the clinical team should be prepared to answer at each visit.

Questions for the Pediatric Hepatologist

• What is my child's current fibrosis stage, and has it changed since the last biopsy?
• Does my child's disease pattern look like "type 2" pediatric MASH (portal-predominant), and does that change monitoring frequency?
• At what fibrosis stage should we begin planning for adult pharmacotherapy eligibility?
• Is my child eligible for any current clinical trials of liver-directed agents?

Questions for the Receiving Adult Hepatologist

• Does my current fibrosis stage and biopsy history qualify me for resmetirom under the approved label?
• Should I have a new liver biopsy or FibroScan to confirm current stage before starting treatment?
• Are there clinical trials of resmetirom or other MASH agents I should consider before or alongside standard-of-care treatment?
• How do my lipid levels and thyroid function need to be monitored on resmetirom?

Monitoring Resmetirom in Adults Who Were Diagnosed as Children

Young adults (18-25) who initiated MASH management in childhood and transition to resmetirom therapy carry a distinct clinical profile compared to patients who present de novo in midlife. Their disease duration is longer, their metabolic comorbidities may be more entrenched, and their baseline fibrosis stage at the time of adult presentation may be higher.

Baseline Labs Before Starting Resmetirom

The Rezdiffra prescribing information specifies that thyroid-stimulating hormone (TSH) should be assessed before initiating therapy, as resmetirom can reduce TSH through pituitary THR-beta activation. Other pre-treatment labs recommended by clinical practice include [2]:

• Liver function tests: ALT, AST, total bilirubin, alkaline phosphatase
• Fasting lipid panel
• HbA1c and fasting glucose
• INR in patients with suspected advanced fibrosis

Drug Interactions Relevant to Metabolically Complex Young Adults

Young adults transitioning from pediatric care often carry polypharmacy burdens related to metabolic syndrome management. Resmetirom is a substrate of CYP3A4 and a P-glycoprotein inhibitor. Co-administration with cyclosporine, rifampin, or strong CYP3A4 inducers requires dose review. The full interaction table is available in the FDA-approved prescribing label [2].

Monitoring Frequency During Resmetirom Therapy

MAESTRO-NASH used quarterly LFT and lipid monitoring through 52 weeks [1]. Applying this schedule to young adult transitioners is reasonable. Elevated ALT above three times the upper limit of normal persisting beyond 4 weeks should prompt dose reassessment or drug discontinuation per labeling.